D. Boral Capital Reiterates “Buy” Rating for Pulmonx (NASDAQ:LUNG)

Pulmonx (NASDAQ:LUNG)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $14.00 price objective on the stock.

A number of other research firms have also recently weighed in on LUNG. Wall Street Zen upgraded Pulmonx from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Lake Street Capital dropped their price objective on shares of Pulmonx from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, October 28th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research note on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pulmonx currently has an average rating of “Hold” and an average price target of $6.81.

Pulmonx Stock Performance

LUNG opened at $1.42 on Friday. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62. Pulmonx has a 12-month low of $1.31 and a 12-month high of $9.37. The business has a 50 day moving average of $1.94 and a 200-day moving average of $1.79. The stock has a market cap of $58.58 million, a price-to-earnings ratio of -1.01 and a beta of 0.07.

Hedge Funds Weigh In On Pulmonx

A number of hedge funds have recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Pulmonx by 32.1% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 218,758 shares of the company’s stock worth $567,000 after purchasing an additional 53,148 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund acquired a new stake in shares of Pulmonx in the second quarter valued at approximately $197,000. R Squared Ltd bought a new stake in shares of Pulmonx in the second quarter valued at approximately $41,000. Squarepoint Ops LLC acquired a new stake in Pulmonx during the fourth quarter worth approximately $91,000. Finally, Two Sigma Investments LP increased its stake in Pulmonx by 50.3% during the 3rd quarter. Two Sigma Investments LP now owns 46,456 shares of the company’s stock worth $75,000 after acquiring an additional 15,557 shares during the period. 91.04% of the stock is owned by institutional investors.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.